Page 10«..9101112..2030..»

Immunicum AB (publ) Announces New Interim CFO Lotta Ferm

By Dr. Matthew Watson

Press Release

Link:
Immunicum AB (publ) Announces New Interim CFO Lotta Ferm

To Read More: Immunicum AB (publ) Announces New Interim CFO Lotta Ferm
categoriaGlobal News Feed commentoComments Off on Immunicum AB (publ) Announces New Interim CFO Lotta Ferm | dataFebruary 1st, 2021
Read All

Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

By Dr. Matthew Watson

Orphazyme A/SCompany announcement                                                                                       No. 02/2021                                                                                                          Company Registration No. 32266355

Read the original post:
Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares

To Read More: Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
categoriaGlobal News Feed commentoComments Off on Capital increase of 170,131 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares | dataFebruary 1st, 2021
Read All

Seer Announces Closing of Public Offering of Common Stock

By Dr. Matthew Watson

REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share, before deducting underwriting discounts and commissions. Of the 3,750,000 shares sold in the offering, 1,650,000 were sold by Seer and 2,100,000 were sold by selling stockholders of Seer.

Read more:
Seer Announces Closing of Public Offering of Common Stock

To Read More: Seer Announces Closing of Public Offering of Common Stock
categoriaGlobal News Feed commentoComments Off on Seer Announces Closing of Public Offering of Common Stock | dataFebruary 1st, 2021
Read All

argenx announces launch of proposed global offering

By Dr. Matthew Watson

Regulated information — Inside information

See the article here:
argenx announces launch of proposed global offering

To Read More: argenx announces launch of proposed global offering
categoriaGlobal News Feed commentoComments Off on argenx announces launch of proposed global offering | dataFebruary 1st, 2021
Read All

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

By Dr. Matthew Watson

BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 29, 2021, the Company granted stock options and restricted stock units to 92 new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.

Read more:
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

To Read More: Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | dataFebruary 1st, 2021
Read All

Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

By Dr. Matthew Watson

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Officer (CFO), effective as of March 12, 2021. Mr. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business continuity. Mr. Sender informed Nabriva that he plans to focus on his three public company Board roles and providing financial advisory services. A search has been initiated to identify a new CFO.

Read the original here:
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

To Read More: Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on Nabriva Therapeutics Announces Retirement of its Chief Financial Officer | dataFebruary 1st, 2021
Read All

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

By Dr. Matthew Watson

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ap9

More here:
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

To Read More: DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
categoriaGlobal News Feed commentoComments Off on DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 | dataFebruary 1st, 2021
Read All

Grant of Restricted Stock Units and Warrants to Employees in Genmab

By Dr. Matthew Watson

Company Announcement

Original post:
Grant of Restricted Stock Units and Warrants to Employees in Genmab

To Read More: Grant of Restricted Stock Units and Warrants to Employees in Genmab
categoriaGlobal News Feed commentoComments Off on Grant of Restricted Stock Units and Warrants to Employees in Genmab | dataJanuary 31st, 2021
Read All

10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

By Dr. Matthew Watson

PLEASANTON, Calif., Jan. 28, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2020 after market close on Wednesday, February 17, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Read the original post:
10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021

To Read More: 10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
categoriaGlobal News Feed commentoComments Off on 10x Genomics to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021 | dataJanuary 31st, 2021
Read All

Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020

By Dr. Matthew Watson

NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the second quarter ended December 31, 2020.

View post:
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020

To Read More: Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
categoriaGlobal News Feed commentoComments Off on Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020 | dataJanuary 31st, 2021
Read All

Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

By Dr. Matthew Watson

Follow this link:
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

To Read More: Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021
categoriaGlobal News Feed commentoComments Off on Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021 | dataJanuary 31st, 2021
Read All

AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

By Dr. Matthew Watson

AIM is Working to Develop an Effective COVID-19 Intranasal Therapy AIM is Working to Develop an Effective COVID-19 Intranasal Therapy

More:
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

To Read More: AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
categoriaGlobal News Feed commentoComments Off on AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen | dataJanuary 31st, 2021
Read All

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

By Dr. Matthew Watson

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

See more here:
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

To Read More: Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
categoriaGlobal News Feed commentoComments Off on Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board | dataJanuary 31st, 2021
Read All

MediPharm Labs Appoints New Chief Financial Officer

By Dr. Matthew Watson

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce Greg Hunter will join MediPharm Labs as Chief Financial Officer (CFO), effective February 8, 2021.

Continued here:
MediPharm Labs Appoints New Chief Financial Officer

To Read More: MediPharm Labs Appoints New Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on MediPharm Labs Appoints New Chief Financial Officer | dataJanuary 31st, 2021
Read All

Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer

By Dr. Matthew Watson

Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021 Commercial Launch of Libmeldy™ in Europe On-Track for 1H 2021

Visit link:
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer

To Read More: Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
categoriaGlobal News Feed commentoComments Off on Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer | dataJanuary 31st, 2021
Read All

OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs

By Dr. Matthew Watson

WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.

Visit link:
OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs

To Read More: OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs
categoriaGlobal News Feed commentoComments Off on OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs | dataJanuary 31st, 2021
Read All

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

By Dr. Matthew Watson

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021

More here:
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

To Read More: Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
categoriaGlobal News Feed commentoComments Off on Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab | dataJanuary 31st, 2021
Read All

Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility

By Dr. Matthew Watson

TORONTO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (“Psyence” or the “Company”) is pleased to announce that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium production facility in Lesotho which has been designed and built to the highest international standards.

Original post:
Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility

To Read More: Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility
categoriaGlobal News Feed commentoComments Off on Psyence Group Completes First Cultivation Cycle of Medical Psilocybin Mushrooms at Its Commercially Licensed Facility | dataJanuary 31st, 2021
Read All

Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis

By Dr. Matthew Watson

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis.

More:
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis

To Read More: Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
categoriaGlobal News Feed commentoComments Off on Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis | dataJanuary 31st, 2021
Read All

Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive…

By Dr. Matthew Watson

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, announced updated interim findings from the ongoing TRIDENT-1 registrational study of lead drug candidate repotrectinib in patients with ROS1-positive TKI-naïve non-small cell lung cancer (NSCLC).

View original post here:
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive...

To Read More: Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive…
categoriaGlobal News Feed commentoComments Off on Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive… | dataJanuary 31st, 2021
Read All

Page 10«..9101112..2030..»